Senesco Technologies, Inc., ("Senesco" or the "Company") announced today that it has demonstrated the efficacy of its gene technology by creating an improved tomato fruit. The result of this major development is a tomato fruit with significantly extended shelf life and other valuable characteristics.

Altering gene expression has yielded tomatoes with a thirty to forty day shelf life, while tomatoes without altered gene expression last only fifteen to twenty days. In addition, this change in gene expression gives rise to larger plants with the potential to produce more fruit.

John E. Thompson, Ph.D., Executive Vice-President of Research and Development, commented, "Our results are extraordinary. In addition to results in Arabidopsis plants (Arabidopsis thaliana), announced on February 17, 2000, we now have validation in a commercially valuable crop that reducing the expression of the DHS gene confers significant resistance to spoilage, thereby extending shelf life. We are eager to apply our technology to other commercially valuable plants now that we have demonstrated its efficacy in a major horticultural crop."

Senesco's technology intercedes once ripening is complete and spoilage is about to begin. This ensures that taste, texture and other features will not change, which was a major difficulty encountered in previous attempts to engineer a tomato with extended shelf life.

Consistent with the Company's commercialization strategy, Senesco is engaged in discussions with several companies interested in entering into licensing agreements and strategic relationships for the use of the Company's technology in fruits, flowers, vegetables and agronomic crops.

Senesco is an agrobiotechnology company whose mission is to enhance crop quality and productivity through the control of senescence (aging) which will result in longer shelf life and increased crop yield. The Company is based in Princeton, New Jersey.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.